Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06980116CT.gov Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Waldenstrom Macroglobulinemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| exs73565 (this asset) | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | P1 | CC · 43 |
| Etoposide | Fred Hutchinson Cancer Center | P2 | BBB |
| Cyclophosphamide | Institute of Hematology & Blood Diseases Hospital, China | P2 | BBB |
| Fludarabine | Institute of Hematology & Blood Diseases Hospital, China | P3 | BBB |
| Prednisone | BeOne Medicines | P2 | BBB |
| Adriamycin | BeOne Medicines | P2 | BBB |
| Bortezomib | Seoul National University Hospital | P2 | BB |
| Cediranib | National Cancer Institute (NCI) | P2 | BB |
| Romidepsin | Mayo Clinic | P2 | BB |
+42 more in the Waldenstrom Macroglobulinemia cohort
Other indications for exs73565
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | P1 | CC · 43 |
| Marginal Zone Lymphoma | — | P1 | CC · 43 |
| Diffuse Large B-Cell Lymphoma | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. exs73565 in Waldenstrom Macroglobulinemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/exs73565-waldenstrom-macroglobulinemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →